BPC-157: What to Know About the Evidence and Its FDA Status

You have probably seen BPC-157 mentioned in a podcast, a gym forum, or an ad promising faster recovery. Maybe you are dealing with a stubborn injury, ongoing gut trouble, or you just want to feel like your body bounces back the way it used to. So you start searching, and within a few minutes you run into a wall of confident claims and almost no straight answers about whether any of it is real or safe.

This article is here to give you the plain version. We will walk through what BPC-157 actually is, what the evidence does and does not show, and where it stands with the U.S. Food and Drug Administration as of mid-2026. This is educational information, not medical advice. It is meant to help you ask better questions, not to tell you what to do with your body.

What BPC-157 is

BPC-157 stands for "Body Protection Compound-157." It is a peptide, which is a short chain of amino acids. The version studied in labs is a synthetic copy of a fragment that researchers originally identified in human gastric (stomach) juice ^[1]. People take it hoping it will speed up recovery from injuries or calm down gut problems. It is most often sold as an injectable or capsule, frequently marketed as a "research chemical" or supplement.

One important point up front: most of what has been studied was given to animals, usually rats, by injection ^[1]. That detail matters a lot, and we will come back to it.

What the evidence actually shows

Here is where it pays to slow down. In 2025, a team of orthopedic and sports medicine researchers published a systematic review in the HSS Journal that gathered every English-language study they could find on BPC-157 from 1993 through mid-2024 ^[1]. A systematic review is a structured attempt to look at all the research at once, rather than cherry-picking the studies that sound exciting.

They found 544 articles. After removing duplicates and screening for quality, 36 studies met their criteria. Of those 36, 35 were preclinical — meaning done in cells or animals, not people. Only one was a human study ^[1].

That one human study was small and retrospective (meaning researchers looked backward at records rather than running a controlled trial). It described 12 people who received a BPC-157 injection into the knee for chronic knee pain; 7 of the 12 reported relief lasting more than six months ^[1]. That is interesting, but 12 people with no comparison group cannot tell you whether the peptide caused the relief, whether it would do anything for you, or whether it is safe over time.

The animal studies are more numerous and, in rats, researchers reported improvements in measures of muscle, tendon, ligament, and bone healing ^[1]. But results in rats do not reliably carry over to humans. Animal bodies process substances differently, doses are not directly comparable, and many things that look helpful in rats have failed or caused harm in people. The review's own authors describe the early findings as "promising" while stating plainly that there is no clinical safety data in humans ^[1].

To put it simply: the encouraging recovery-related claims you see online are built almost entirely on animal research. The human evidence is one small look-back study. That is a real evidence gap, not settled science.

The first rigorous human trial is only just beginning

If you want a snapshot of how early this all is, look at the clinical trial registry. In February 2026, a Phase 2 randomized, double-blind, placebo-controlled trial of BPC-157 for acute hamstring strains began at a hospital in China ^[2]. This is the kind of study — randomized, blinded, with a placebo group — that can actually start to answer whether BPC-157 does anything and how it behaves in people.

It is estimated to finish around 2028 ^[2]. In other words, as of 2026, the rigorous human research most people assume already exists is, in fact, just getting underway.

What the FDA has said — and how it changed in 2026

This is the part to read carefully, because the regulatory status is specific and it has been moving.

First, the baseline that has not changed: BPC-157 is not an FDA-approved drug ^[3]. There is no FDA-approved BPC-157 product on the U.S. market, and BPC-157 has never been cleared for sale or for general pharmacy compounding.

The rest of the story sits in the world of compounding. Compounding is when a licensed pharmacy makes a customized medication for an individual patient. As a general rule, compounded medications are not FDA approved — the FDA does not verify their safety, effectiveness, or quality the way it does for approved drugs ^[3]. Under federal law, pharmacies can only compound from certain permitted raw ingredients, called bulk drug substances.

In September 2023, the FDA placed BPC-157 in a category of substances flagged for significant safety risks under section 503A, which effectively kept it out of compounding ^[3]. The FDA's written reasoning is worth understanding in plain terms. The agency stated that compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration" (meaning your immune system might react to it), and that there are "complexities" in confirming the purity and identity of the ingredient. Most directly, the FDA said it "has identified no, or only limited, safety-related information for the proposed routes of administration," and therefore "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans" ^[3].

Read that line again. The FDA was not saying BPC-157 is proven dangerous. It was saying it does not have enough information to know whether it is safe — which, for something people are injecting, is its own kind of warning.

Then it shifted. In April 2026, the FDA removed BPC-157 (along with several other peptides) from that significant-safety-risks list, effective later that month, after the original nominations supporting the listing were withdrawn ^[4]. It is easy to misread that headline, so here is the careful version: removal from the risk list is not FDA approval, and it does not mean BPC-157 is now cleared for compounding. These peptides were never on the approved-for-compounding list to begin with ^[4]. The FDA has also scheduled its advisory committee to review BPC-157 and similar peptides in mid-2026, and any path toward allowing compounding would still require a formal rulemaking process that can take a long time ^[4].

The honest read of all that: the regulatory picture is in flux, the underlying safety questions the FDA raised have not been answered by new human data, and "removed from a risk list" is not the same as "shown to be safe." If you are reading this later than mid-2026, the specifics may have moved again, so the current FDA pages are the place to check rather than any single article.

Why "where it comes from" is a real risk

Because there is no FDA-approved BPC-157 product, anything sold under that name is made and sold outside the system that normally checks a drug's identity, purity, and dose. The FDA specifically pointed to the difficulty of characterizing the ingredient and the possibility of peptide-related impurities ^[3]. The systematic review made the same point from a different angle, noting that potential harms could come from "unregulated manufacturing, contamination, or unknown clinical safety" ^[1].

So even setting aside whether BPC-157 itself does anything, there is a separate question you cannot easily answer as a consumer: is what is actually in the vial what the label claims, and is it free of contaminants? With an unregulated product, you generally cannot know.

One more thing if you compete in sports

If you are a competitive or tested athlete, this is non-negotiable to know. The World Anti-Doping Agency added BPC-157 to its Prohibited List effective January 1, 2022, and it remains prohibited; it sits in the "non-approved substances" category, which covers experimental substances not approved for human use ^[5]. Using it can result in a doping violation regardless of how it is sold.

The honest bottom line

Here is the whole picture in a few sentences. BPC-157 is an experimental peptide. Almost all of the encouraging research is in animals, the human evidence is currently one small look-back study, and the first rigorous human trial is only now running ^[1][2]. It is not FDA approved and has never been cleared for compounding; the FDA flagged it for safety concerns in 2023, then removed it from that risk list in 2026 after the nominations were withdrawn — a change that is not approval and that did not answer the agency's underlying question of whether it would harm people ^[3][4]. It is also banned in tested sport ^[5].

None of that proves it is harmful. It proves that the questions you would want answered — does it actually do anything, is it safe, and is the product even what it claims to be — mostly do not have answers yet. If you are weighing it, that uncertainty is the single most important fact, and it is worth discussing with a licensed clinician who knows your full history before you decide anything.

We are building a longevity platform around exactly these kinds of decisions: looking honestly at the evidence, distinguishing animal data from human data, and being upfront about what is still unknown. To be clear, Velri does not offer, sell, or prescribe BPC-157, and nothing here is a recommendation to use it. If our approach resonates with you, join the waitlist and we will keep you posted as we open up.

*This article is for general education and is not medical advice. It does not recommend or endorse the use of any specific substance. Compounded medications are not FDA approved. Any decision about a medication should be made with a licensed healthcare professional, and only if it is prescribed for you after a review of your individual situation.*